Rachel A Sanford1, Juhee Song2, Angelica M Gutierrez-Barrera3, Jessica Profato4, Ashley Woodson4, Jennifer Keating Litton3, Isabelle Bedrosian5, Constance T Albarracin6, Vicente Valero3, Banu Arun3. 1. Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 4. Department of Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 6. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
BACKGROUND: The 2015 National Comprehensive Cancer Network guidelines recommend that genetic counseling and germline BRCA mutation testing be offered to women under age 60 with triple-negative breast cancer (TNBC). As a result of the 2010 American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines for breast cancer, patients with breast cancers that are estrogen receptor (ER) or progesterone receptor (PR) low-positive (1%-9% on immunohistochemistry) are no longer strictly considered to have TNBC and may not be referred for genetic counseling. However, the incidence of BRCA mutation in patients with hormone receptor (HR) low-positive breast cancers remains unknown, and current ASCO/CAP guidelines may result in undertesting for BRCA mutations. METHODS: A prospectively maintained research database of breast cancer patients evaluated at The University of Texas MD Anderson Cancer Center between 2004 and 2014 was reviewed; 314 patients were identified with HER2/neu-negative breast cancers expressing ER and PR <10% with known BRCA mutation status. RESULTS: Three hundred fourteen patients had breast cancers expressing ER and PR <10%; 238 (75.8%) had HR-negative cancers (<1% ER and PR), and 76 (24.2%) had HR-low-positive cancers (1%-9% ER and/or PR). Among patients with HR-negative tumors, 86 of 238 (36.1%) had a BRCA1/2 mutation, whereas in the HR-low-positive group, 30 of 76 (39.5%) had a BRCA1/2 mutation. In multivariate analysis, HR status (<1% vs 1%-9%) was not significantly associated with BRCA1/2 mutations. CONCLUSIONS: The incidence of BRCA1/2 mutations is similar in patients with HR-low-positive breast cancer and patients with HR-negative breast cancer. Genetic counseling and BRCA testing should be offered to patients under age 60 who have HR-low-positive breast cancers. Cancer 2015;121:3435-43.
BACKGROUND: The 2015 National Comprehensive Cancer Network guidelines recommend that genetic counseling and germline BRCA mutation testing be offered to women under age 60 with triple-negative breast cancer (TNBC). As a result of the 2010 American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines for breast cancer, patients with breast cancers that are estrogen receptor (ER) or progesterone receptor (PR) low-positive (1%-9% on immunohistochemistry) are no longer strictly considered to have TNBC and may not be referred for genetic counseling. However, the incidence of BRCA mutation in patients with hormone receptor (HR) low-positive breast cancers remains unknown, and current ASCO/CAP guidelines may result in undertesting for BRCA mutations. METHODS: A prospectively maintained research database of breast cancerpatients evaluated at The University of Texas MD Anderson Cancer Center between 2004 and 2014 was reviewed; 314 patients were identified with HER2/neu-negative breast cancers expressing ER and PR <10% with known BRCA mutation status. RESULTS: Three hundred fourteen patients had breast cancers expressing ER and PR <10%; 238 (75.8%) had HR-negative cancers (<1% ER and PR), and 76 (24.2%) had HR-low-positive cancers (1%-9% ER and/or PR). Among patients with HR-negative tumors, 86 of 238 (36.1%) had a BRCA1/2 mutation, whereas in the HR-low-positive group, 30 of 76 (39.5%) had a BRCA1/2 mutation. In multivariate analysis, HR status (<1% vs 1%-9%) was not significantly associated with BRCA1/2 mutations. CONCLUSIONS: The incidence of BRCA1/2 mutations is similar in patients with HR-low-positive breast cancer and patients with HR-negative breast cancer. Genetic counseling and BRCA testing should be offered to patients under age 60 who have HR-low-positive breast cancers. Cancer 2015;121:3435-43.
Authors: Takayuki Iwamoto; Daniel Booser; Vicente Valero; James L Murray; Kimberly Koenig; Francisco J Esteva; Naoto T Ueno; Jie Zhang; Weiwei Shi; Yuan Qi; Junji Matsuoka; Elliana J Yang; Gabriel N Hortobagyi; Christos Hatzis; W Fraser Symmans; Lajos Pusztai Journal: J Clin Oncol Date: 2012-01-30 Impact factor: 44.544
Authors: B Zafrani; M H Aubriot; E Mouret; P De Crémoux; Y De Rycke; A Nicolas; E Boudou; A Vincent-Salomon; H Magdelénat; X Sastre-Garau Journal: Histopathology Date: 2000-12 Impact factor: 5.087
Authors: Deann P Atchley; Constance T Albarracin; Adriana Lopez; Vicente Valero; Christopher I Amos; Ana Maria Gonzalez-Angulo; Gabriel N Hortobagyi; Banu K Arun Journal: J Clin Oncol Date: 2008-09-10 Impact factor: 44.544
Authors: Mary B Daly; Robert Pilarski; Jennifer E Axilbund; Saundra S Buys; Beth Crawford; Susan Friedman; Judy E Garber; Carolyn Horton; Virginia Kaklamani; Catherine Klein; Wendy Kohlmann; Allison Kurian; Jennifer Litton; Lisa Madlensky; P Kelly Marcom; Sofia D Merajver; Kenneth Offit; Tuya Pal; Boris Pasche; Gwen Reiser; Kristen Mahoney Shannon; Elizabeth Swisher; Nicoleta C Voian; Jeffrey N Weitzel; Alison Whelan; Georgia L Wiesner; Mary A Dwyer; Rashmi Kumar Journal: J Natl Compr Canc Netw Date: 2014-09 Impact factor: 11.908
Authors: C Davies; J Godwin; R Gray; M Clarke; D Cutter; S Darby; P McGale; H C Pan; C Taylor; Y C Wang; M Dowsett; J Ingle; R Peto Journal: Lancet Date: 2011-07-28 Impact factor: 79.321
Authors: S R Young; Robert T Pilarski; Talia Donenberg; Charles Shapiro; Lyn S Hammond; Judith Miller; Karen A Brooks; Stephanie Cohen; Beverly Tenenholz; Damini Desai; Inuk Zandvakili; Robert Royer; Song Li; Steven A Narod Journal: BMC Cancer Date: 2009-03-19 Impact factor: 4.430